Literature DB >> 22101903

Novel options for the treatment of castration-resistant prostate cancer.

Carsten-H Ohlmann1, Axel S Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J Mathers, Patrick J Bastian.   

Abstract

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22101903     DOI： 10.1007/s00345-011-0796-7

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  55 in total

1.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

Authors:  Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.

Authors:  C Huggins
Journal:  Ann Surg       Date:  1942-06       Impact factor: 12.969

3.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

4.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Authors:  Kim N Chi; Elizabeth Eisenhauer; Ladan Fazli; Edward C Jones; S Larry Goldenberg; Jean Powers; Dongsheng Tu; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.

Authors:  Michael A Carducci; Joel B Nelson; M Kathy Bowling; Theresa Rogers; Mario A Eisenberger; Victoria Sinibaldi; Ross Donehower; Terri L Leahy; Robert A Carr; Jeffrey D Isaacson; Todd J Janus; Amy Andre; Balakrishna S Hosmane; Robert J Padley
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Authors:  Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544
View more
  6 in total

Review 1.  The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.

Authors:  Bradley C Holland; Zubin Shetty; Shaheen Alanee
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

2.  Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Authors:  Daniel P Petrylak; Jitendra G Gandhi; William R Clark; Elisabeth Heath; Jianqing Lin; William K Oh; David B Agus; Bradley Carthon; Susan Moran; Ning Kong; Ajit Suri; Michael Bargfrede; Glenn Liu
Journal:  Invest New Drugs       Date:  2015-01-04       Impact factor: 3.850

Review 3.  Targeted α-particle therapy of bone metastases in prostate cancer.

Authors:  Hossein Jadvar; David I Quinn
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

4.  Is there an anti-androgen withdrawal syndrome for enzalutamide?

Authors:  Christoph A J von Klot; Mario W Kramer; Alena Böker; Thomas R W Herrmann; Inga Peters; Markus A Kuczyk; Uwe Ligges; Jürgen E Gschwend; Margitta Retz; Sebastian C Schmid; Arnulf Stenzl; Christian Schwentner; Tilmann Todenhöfer; Michael Stöckle; Carsten-Henning Ohlmann; Ines Azone; René Mager; Georg Bartsch; Axel Haferkamp; Axel Heidenreich; Charlotte Piper; Axel S Merseburger
Journal:  World J Urol       Date:  2014-04-02       Impact factor: 4.226

5.  Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.

Authors:  Jeetendra Eswaraka; Anand Giddabasappa; Guangzhou Han; Kush Lalwani; Koleen Eisele; Zheng Feng; Timothy Affolter; James Christensen; Gang Li
Journal:  BMC Cancer       Date:  2014-10-02       Impact factor: 4.430

6.  Enzalutamide in European and North American men participating in the AFFIRM trial.

Authors:  Axel S Merseburger; Howard I Scher; Joaquim Bellmunt; Kurt Miller; Peter F A Mulders; Arnulf Stenzl; Cora N Sternberg; Karim Fizazi; Mohammad Hirmand; Billy Franks; Gabriel P Haas; Johann de Bono; Ronald de Wit
Journal:  BJU Int       Date:  2014-10-23       Impact factor: 5.588
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.